Diabetes is not sufficient justification for IIb/IIIa use in percutaneous coronary intervention

E-ISSN： 1522-726x|86|3|376-377

ISSN： 1522-1946

Source： CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol.86, Iss.3, 2015-09, pp. : 376-377

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 390-396

John Wiley & Sons Inc

Access to resources Recommend Favorite

Short‐ and long‐term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta‐analysis of randomized trials

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 364-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of Some Cardiovascular Risk Factors on the Expression of Platelet Glycoprotein IIb/IIIa Receptors in Patients with Myocardial Infarction Treated with Antiplatelet Drugs under Primary Percutaneous Coronary Intervention

By Konopka Anna

Molecular Diagnosis & Therapy, Vol. 13, Iss. 6, 2009-12 ,pp. : 375-382

Adis International

Access to resources Recommend Favorite

Effects of Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban on Minor Myocardial Damage in Angiographically Successful Percutaneous Coronary Angioplasty

Cardiology, Vol. 102, Iss. 1, 2004-04 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Coronary Revascularization

Pathophysiology of Haemostasis and Thrombosis, Vol. 29, Iss. 1, 2004-11 ,pp. : 69-71

Karger

Access to resources Recommend Favorite